Skip to Content
Merck
CN

13-1890

Hydrofluoric acid

55%, CP

Synonym(s):

HF

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
HF
CAS Number:
Molecular Weight:
20.01
UNSPSC Code:
12352106
PubChem Substance ID:
MDL number:
Concentration:
55%
Form:
liquid
Grade:
CP
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


grade

CP

vapor density

1.27 (vs air)

vapor pressure

25 mmHg ( 20 °C)

form

liquid

availability

available only in Japan

concentration

55%

density

1.15 g/mL at 25 °C (lit.)

SMILES string

[H+].[F-]

InChI

1S/FH/h1H

InChI key

KRHYYFGTRYWZRS-UHFFFAOYSA-N



Still not finding the right product?

Explore all of our products under Hydrofluoric acid


pictograms

Skull and crossbonesCorrosion

signalword

Danger

Hazard Classifications

Acute Tox. 1 Dermal - Acute Tox. 2 Inhalation - Acute Tox. 2 Oral - Eye Dam. 1 - Skin Corr. 1A

Storage Class

6.1B - Non-combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品

This item has



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Ian Ford et al.
International journal of cardiology, 184, 163-169 (2015-02-24)
We identified easily obtained baseline characteristics associated with outcomes in patients with chronic heart failure (HF) and elevated heart rate (HR) receiving contemporary guideline-recommended therapy in the SHIFT trial, and used them to develop a prognostic model. We selected the
Faiez Zannad et al.
European journal of heart failure, 17(7), 735-742 (2015-04-29)
Thrombin is a critical element of crosstalk between pathways contributing to worsening of established heart failure (HF). The aim of this study is to explore the efficacy and safety of rivaroxaban 2.5 mg bid compared with placebo (with standard care) after
Philip J Millar et al.
Circulation, 131(5), 459-468 (2014-12-04)
Muscle sympathetic activation in heart failure with reduced ejection fraction (HFrEF) has been attributed, on the basis of multiunit recordings, to attenuated inhibitory feedback from stretch-sensitive cardiopulmonary mechanoreceptors. However, such preparations integrate 2 populations of single units exhibiting directionally opposite